JMP Securities Sticks to Its Buy Rating for Applied Molecular Transport (AMTI)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Applied Molecular Transport (AMTIResearch Report), with a price target of $21.00. The company’s shares opened today at $2.09.

According to TipRanks, Butler is an analyst with an average return of -4.9% and a 41.42% success rate. Butler covers the Healthcare sector, focusing on stocks such as Concert Pharma, Applied Molecular Transport, and Aquestive Therapeutics.

Currently, the analyst consensus on Applied Molecular Transport is a Strong Buy with an average price target of $9.53.

See Insiders’ Hot Stocks on TipRanks >>

Based on Applied Molecular Transport’s latest earnings release for the quarter ending March 31, the company reported a quarterly a GAAP net loss of $42.58 million. In comparison, last year the company had a GAAP net loss of $20.46 million

Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMTI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Applied Molecular Transport Inc is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. Its proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Its product candidate, AMT-101, is an oral IL-10 fusion protein that has been designed for active transport across the IE barrier into local GI tissue. IL-10 is a potent immunomodulatory cytokine that is known to be the master regulator of immune homeostasis, including within GI mucosal tissue.

Read More on AMTI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More